Mitral Valve Regurgitation

Clinical Trial Finder

Many patients with mitral valve regurgitation are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

Annular Contraction for Transcatheter Treatment of Insufficient Mitral ValvE

Conditions:   Mitral Valve Insufficiency;   Cardiac Valve Annuloplasty;   Mitral Valve Annuloplasty;   Cardiovascular Diseases;   Heart Diseases;   Heart Valve Diseases;   Mitral Regurgitation
Intervention:   Device: Cardioband Mitral System
Sponsor:   Valtech Cardio Ltd
Not yet recruiting - verified January 2017

MitraClip® and Hemodynamic Effects of Iatrogenic Atrial Septum Defect Closure

Conditions:   Mitral Valve Insufficiency;   Heart Septal Defects, Atrial
Intervention:   Device: Figulla Flex Occluder (Occlutech)
Sponsor:   University of Leipzig
Recruiting - verified January 2017

NHLBI DIR LAMPOON Study: Intentional Laceration of the Anterior Mitral Leaflet to Prevent Left Ventricular Outflow Tract Obstruction During Transcatheter Mitral Valve Implantation

Condition:   Mitral Valve Failure
Interventions:   Device: Edwards SAPIEN 3 transcatheter heart valve;   Device: ASHI INTECC Astato XS 20
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Not yet recruiting - verified January 2017

Trial on Safety and Efficacy of Velmanase Alfa Treatment in Pediatric Patients With Alpha-Mannosidosis

Condition:   Alpha-Mannosidosis
Intervention:   Drug: Velmanase Alfa (e.g. Lamazym)
Sponsors:   Chiesi Farmaceutici S.p.A.;   Cromsource
Recruiting - verified January 2017

Efficacity of Idelalisib and Obinutuzumab in Patient With Relapsed Refractory Waldenstrom's Macroglobulinemia

Condition:   Waldenstrom Macroglobulinemia
Interventions:   Drug: Obinutuzumab;   Drug: Idelalisib
Sponsor:   French Innovative Leukemia Organisation
Not yet recruiting - verified January 2017

Safety and Efficacy of Alteplase When Administered in Chinese Patients With Acute Ischemic Hemispheric Stroke Where Thrombolysis is Initiated Between 3 and 4.5 Hours After Stroke Onset

Condition:   Stroke
Intervention:   Drug: alteplase
Sponsor:   Boehringer Ingelheim
Recruiting - verified January 2017

Effectiveness and Safety of SAR156597 in Treating Diffuse Systemic Sclerosis

Condition:   Systemic Sclerosis
Interventions:   Drug: SAR156597 (ACT14604);   Drug: Placebo
Sponsor:   Sanofi
Recruiting - verified January 2017

The Ruxolitinib Versus Best Available Therapy Trial in Patients With High Risk ET in Second Line

Condition:   Essential Thrombocythemia
Interventions:   Drug: Anagrelide;   Drug: Ruxolitinib (JAKAVI®);   Drug: IFNα/ PegIFNα
Sponsors:   French Innovative Leukemia Organisation;   Novartis Pharmaceuticals
Recruiting - verified October 2016

Integrating Quantitative Energetics Determines the Microbiome's Contribution to Energy Balance

Condition:   Obesity
Interventions:   Other: Dual-energy X-ray absorptiometry (DEXA)/ Magnetic resonance spectroscopy (MRS);   Other: 23-hour Metabolic Calorimetry;   Other: Whole Room Calorimetry;   Other: Polyethylene glycol (PEG)
Sponsors:   Translational Research Institute for Metabolism and Diabetes, Florida;   Arizona State University;   Pennington Biomedical Research Center;   University of Florida
Recruiting - verified January 2017

ENRICH: Early MiNimally-invasive Removal of IntraCerebral Hemorrhage (ICH)

Condition:   Cerebral Hemorrhage
Intervention:   Procedure: Early Surgical Hematoma Evacuation
Sponsors:   Nico Corporation;   Emory University
Recruiting - verified January 2017

Intermittent Oro-Esophageal Tube Feeding Using Individually-Customized 3-Dimensional Printing

Condition:   Dysphagia
Intervention:   Procedure: VFSS
Sponsor:   Ulsan University Hospital
Recruiting - verified January 2017

A Study Comparing the Effect of Albiglutide With Exenatide on Regional Brain Activity Related to Nausea in Healthy Subjects

Condition:   Diabetes Mellitus
Interventions:   Drug: Albiglutide 50mg;   Drug: Albiglutide matching placebo;   Drug: Exenatide 10microgram;   Drug: Exenatide placebo (saline)
Sponsors:   GlaxoSmithKline;   The General Hospital Corporation d/b/a Massachusetts General Hospital
Recruiting - verified January 2017

Neuroform Atlas Stent for Intracranial Aneurysm Treatment

Condition:   Intracranial Aneurysm
Intervention:  
Sponsor:   Stryker Neurovascular
Recruiting - verified October 2016

International Intracranial Dissection Study

Conditions:   Cerebrovascular Disorders;   Vascular: Intracranial;   Intimal Dissection;   Stroke
Intervention:   Other: No study-specific intervention
Sponsors:   University Hospital Inselspital, Berne;   Swiss Heart Foundation;   Cervical Artery Dissections and Ischemic Stroke Patients - Consortium
Recruiting - verified January 2017

Epigenetic Regulation of Human Adipose Tissue Distribution

Condition:   Obesity
Interventions:   Other: Dual-energy X-ray absorptiometry (DEXA)/ Magnetic resonance imaging (MRI) and Magnetic resonance spectroscopy (MRS);   Procedure: Adipose tissue biopsies;   Other: FSIGTT/ RMR
Sponsors:   Translational Research Institute for Metabolism and Diabetes, Florida;   Sanford-Burnham Medical Research Institute
Recruiting - verified January 2017

Pharmacological Reduction of Functional, Ischemic Mitral REgurgitation

Conditions:   Mitral Valve Insufficiency;   Left Ventricular Dysfunction
Interventions:   Drug: LCZ696;   Drug: Valsartan
Sponsors:   Asan Medical Center;   Novartis
Active, not recruiting - verified January 2017

Development and Validation of Multi-nuclear Magnetic Resonance Imaging and Spectroscopy for Whole Body Human Applications

Conditions:   Human Body Composition;   Human Body Function
Intervention:   Other: To evaluate the reproducibility of acquiring multi-nuclear data on a new 3T Philips Magnet
Sponsor:   Translational Research Institute for Metabolism and Diabetes, Florida
Recruiting - verified January 2017

Study to Assess Management and Outcomes of Hospitalised Patients With Complicated UTI (RESCUING)

Conditions:   Urinary Tract Infections;   Bacterial Resistance
Intervention:  
Sponsors:   Institut d'Investigació Biomèdica de Bellvitge;   Tel Aviv University;   AiCuris Anti-infective Cures GmbH;   University of Bristol;   UMC Utrecht
Completed - verified January 2017

Phase II Trial GA101 Inbrutinib B CLL

Condition:   Leukemia, Lymphocytic, Chronic, B-Cell
Interventions:   Drug: GA101;   Drug: Ibrutinib;   Drug: Cyclophosphamide;   Drug: Fludarabine
Sponsors:   French Innovative Leukemia Organisation;   Roche Pharma AG;   Janssen-Cilag Ltd.
Recruiting - verified January 2017

Neuroimaging Study of Risk Factors for Adolescent Bipolar Disorder

Condition:   Attention Deficit Hyperactivity Disorder
Interventions:   Drug: mixed amphetamine salts-extended release (MAS-XR);   Drug: Placebo
Sponsors:   University of Cincinnati;   National Institute of Mental Health (NIMH)
Recruiting - verified June 2015

Study of Compound Edaravone Injection for Treatment of Acute Ischemic Stroke

Condition:   Acute Ischemic Stroke
Interventions:   Drug: Compound Edaravone Injection;   Drug: Edaravone Injection
Sponsor:   Jiangsu Simcere Pharmaceutical Co., Ltd.
Completed - verified January 2017

Impact of Herniation on WFNS Grading in Spontaneous Subarachnoid Hemorrhage - a SWISS SOS Observational Trial

Condition:   Subarachnoid Hemorrhage
Intervention:   Other: Clinical assessment
Sponsor:   University Hospital Inselspital, Berne
Recruiting - verified January 2017

Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis

Condition:   Scleroderma, Systemic
Interventions:   Drug: Riociguat (Adempas, BAY63-2521);   Drug: Placebo
Sponsor:   Bayer
Recruiting - verified January 2017

Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma

Conditions:   Malignant Glioma;   Refractory Brain Neoplasm;   Recurrent Brain Neoplasm;   Glioblastoma
Interventions:   Biological: IL13Rα2-specific, hinge-optimized, 41BB-costimulatory CAR/truncated CD19-expressing T lymphocytes;   Other: laboratory biomarker analysis;   Other: quality-of-life assessment;   Procedure: Magnetic Resonance Imaging;   Procedure: Magnetic Resonance Spectroscopic Imaging;   Biological: IL13Rα2-specific, hinge-optimized, 41BB-costimulatory CAR/truncated CD19-expressing T lymphocytes
Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
Recruiting - verified January 2017

Clinical Biomarkers in Alpha-mannosidosis

Condition:   Alpha-Mannosidosis
Intervention:  
Sponsor:   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified December 2016

A Pilot Study of Metformin in Patients With a Diagnosis of Li-Fraumeni Syndrome

Condition:   Li-Fraumeni Syndrome
Intervention:   Drug: Metformin
Sponsor:   National Cancer Institute (NCI)
Active, not recruiting - verified November 2016

JAK2 Inhibitors RUXOLITINIB in Patients With Myelofibrosis

Condition:   Myelofibrosis
Intervention:   Drug: Ruxolotinib
Sponsor:   French Innovative Leukemia Organisation
Recruiting - verified January 2017

High-Dose Deferoxamine in Intracerebral Hemorrhage

Condition:   Intracerebral Hemorrhage
Interventions:   Drug: Deferoxamine;   Drug: Normal saline
Sponsors:   Beth Israel Deaconess Medical Center;   Medical University of South Carolina;   National Institute of Neurological Disorders and Stroke (NINDS);   Massachusetts General Hospital;   Tufts Medical Center;   University of Massachusetts, Worcester;   University of Pennsylvania;   Johns Hopkins University;   University of Maryland;   University of Virginia;   Duke University;   University of North Carolina;   University of Florida;   The Cleveland Clinic;   Henry Ford Hospital;   Ohio State University;   St. Joseph's Hospital and Medical Center, Phoenix;   University of California, San Francisco;   Oregon Health and Science University;   Yale New Haven Hospital;   University of Iowa;   Hartford Hospital;   The University of Texas Health Science Center, Houston;   Rhode Island Hospital;   Stanford University;   University of Washington;   University of Calgary;   Hopital de l'Enfant-Jesus;   University of Alberta;   Dalhousie University
Suspended - verified January 2017

Magnetic Resonance Spectroscopy in Autonomic Failure

Conditions:   Pure Autonomic Failure;   Multiple System Atrophy
Intervention:   Procedure: Magnetic Resonance Spectroscopy Imaging
Sponsor:   Vanderbilt University
Terminated - verified January 2017

Magnetic Resonance Imaging and Spectroscopy Biomarkers of Neonatal Hypoxic Ischemic Encephalopathy

Condition:   Hypoxic Ischemic Encephalopathy
Intervention:  
Sponsor:   University Children's Hospital, Zurich
Recruiting - verified January 2017

Identification of Clinically Occult Glioma Cells and Characterization of Glioma Behavior Through Machine Learning Analysis of Advanced Imaging Technology

Condition:   Glioma
Interventions:   Procedure: MRS Imaging;   Procedure: PET Scanning;   Procedure: Diffusion Tensor Imaging
Sponsor:   AHS Cancer Control Alberta
Active, not recruiting - verified July 2016

Phase I Study of Intensity Modulated Radiation Therapy for Prostate Cancer

Condition:   Prostate Cancer
Intervention:   Radiation: Radiation
Sponsor:   National Cancer Institute (NCI)
Completed - verified September 2016

Use of Muscle Spectroscopy to Evaluate Mitochondrial Dysfunction in HIV-Infected Patients

Condition:   HIV Infections
Intervention:  
Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
Withdrawn - verified October 2004